Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis

Abstract

RDP58 at a dose of 200 or 300 mg, but not 100 mg, was effective in mild-to-moderate UC. RDP58 was safe and well tolerated, and its novel action makes it an attractive potential therapy.